Relevant bibliographies by topics / Bisphosphonate

Academic literature on the topic 'Bisphosphonate'

Author: Grafiati
Published: 4 June 2021
Last updated: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Bisphosphonate.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Bisphosphonate"

1

Bergner, R. "Bisphosphonattherapie bei renaler Osteopathie." Osteologie 17, no. 03 (2008): 154–58. http://dx.doi.org/10.1055/s-0037-1619862.

Full text
Abstract:
ZusammenfassungBisphosphonate sind in der Therapie der Osteoporose und maligner Knochenerkrankungen inzwischen Standard. Da Bisphosphonate ausschließlich renal ausgeschieden werden, ist eine schwere Niereninsuffizienz eine Kontraindikation für den Einsatz der meisten Bisphosphonate. Bei Dialysepatienten liegen jedoch in der Regel ausgeprägte Veränderungen des Knochenstoffwechsels vor, die zumindest teilweise den Einsatz von Bisphosphonaten sinnvoll erscheinen lassen. Tierexperimentelle Studien belegen, dass durch die Gabe eines Bisphosphonats die Veränderungen eines hyperparathyreoiden Knochens verhindert werden konnten. Daten zu Clodronat, Pamidronat und Ibandronat zeigen, dass diese Bisphosphonate gut dialysabel sind und ein Einsatz bei Dialysepatienten von dieser Seite her möglich ist. In ersten Pilotstudien an Dialysepatienten konnte dieser positive Effekt aus den tierexperimentellen Studien bestätigt werden. Es fehlen jedoch derzeit größere placebokontrollierte Studien, die den Einsatz von Bisphosphonaten in der Therapie der renalen Osteopathie soweit belegen, dass dieser als allgemeine Therapieempfehlung ausgesprochen werden kann.
APA, Harvard, Vancouver, ISO, and other styles
2

Anghelescu, Doralina L., Varayini Pankayatselvan, Rosa Nguyen, Deborah Ward, Jianrong Wu, Huiyun Wu, Denaya D. Edwards, and Wayne Furman. "Bisphosphonate Use in Pediatric Oncology for Pain Management." American Journal of Hospice and Palliative Medicine® 36, no. 2 (August 16, 2018): 138–42. http://dx.doi.org/10.1177/1049909118793114.

Full text
Abstract:
The use of bisphosphonates for pain control in children with cancer is not extensively studied. We retrospectively evaluated 35 children with cancer treated with intravenous bisphosphonates for pain management at a single institution from 1998 through 2015. We analyzed pain scores and opioid and adjuvant medication consumption before bisphosphonate administration, daily for 2 weeks, and at 3 and 4 weeks after administration. We also determined the time interval between diagnosis and first administration of bisphosphonates and duration of life after bisphosphonate administration. Mean pain scores were 2.45 (±2.96) and 0.75 (±1.69) before and 14 days after bisphosphonate administration, respectively ( P = .25), and morphine equivalent doses of opioids were 5.52 (±13.35) and 5.27 (±9.77), respectively ( P = .07). Opioid consumption was significantly decreased at days 4 to 8, days 11 to 12, and week 3 after first bisphosphonate administration. The median duration of life after first bisphosphonate administration was 80 days, indicating its use late in the course of treatment. Bisphosphonates did not significantly improve pain outcomes at 2 weeks, but opioid consumption was reduced at several time points during the first 3 weeks. The use of bisphosphonates earlier in the course of pediatric oncological disease should be evaluated in prospective investigations.
APA, Harvard, Vancouver, ISO, and other styles
3

Klotz, Christopher, Franz Jakob, Matthias Kohl, Simon von Stengel, Uwe Lange, Friederike Thomasius, Katharina Kerschan-Schindl, Michael Uder, and Wolfgang Kemmler. "Effekt von additivem körperlichem Training zur Bisphosphonat-Therapie auf die Knochendichte: Eine systematische Übersichtsarbeit und Meta-Analyse." Osteologie 31, no. 03 (August 2022): 184–94. http://dx.doi.org/10.1055/a-1904-5706.

Full text
Abstract:
Zusammenfassung Hintergrund Körperliches Training und antiresorptive pharmakologische Therapie wirken über unterschiedliche Mechanismen auf den Knochenstoffwechsel ein. Die vorliegende Arbeit beschäftigt sich mit dem Ansatz, ob eine Bisphosphonat-Behandlung durch zusätzliches körperliches Training additive Effekte auf die Knochendichte (BMD) an Lendenwirbelsäule (LWS) und/oder Schenkelhals (SH) ausübt. Methoden Unsere systematische Literaturrecherche von fünf elektronischen Datenbanken gemäß PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) schloss kontrollierten Studien mit einer Dauer von mehr als 6 Monaten und mindestens zwei Studienarmen: (a) Bisphosphonate (B), (b) Bisphosphonate und körperliches Training (B+E) bis zum 26. August 2021, ein. Studien mit anderen pharmazeutischen Therapien oder Krankheiten mit relevanten Auswirkungen auf den Knochenstoffwechsel wurden ausgeschlossen. Die vorliegende Analyse wurde als random-effects Meta-Analyse durchgeführt. Ergebnismaße waren standardisierte mittlere Differenzen (SMD) für BMD-Änderungen an LWS und Schenkelhals (SH). Ergebnisse Unsere Suche identifizierte vier geeignete Studien mit insgesamt 247 Teilnehmern. Zusammenfassend zeigte die kombinierte Intervention (B+E) verglichen mit der isolierten Bisphosphonat-Therapie keine signifikant höheren Effektstärken an LWS (SMD: 0,66, 95%-CI: − 0,63 bis 1,94) oder SH-BMD (0,49 − 0,42 bis 1,40). Wir beobachteten für beide Studienendpunkte (BMD-LWS, BMD-SH) eine sehr hohe Heterogenität der Ergebnisse der eingeschlossenen Studien (I2: 89 bzw. 92%). Die Wahrscheinlichkeit eines „small study“ bzw. Publikations-Bias liegt in beiden Fällen ebenfalls recht hoch. Schlussfolgerung Wir konnten keinen signifikant überlegenen Effekt einer kombinierten Intervention aus Bisphosphonaten und körperlichem Training im Vergleich zu isolierter Bisphosphonat-Therapie auf die BMD an LWS oder SH erfassen. Allerdings zeigten die vorliegenden Einzelstudien eine hohe Heterogenität, die wir primär auf unterschiedlichen Trainingsprotokolle der Studien zurückführen. Schlüsselworte körperliches Training, Bisphosphonate, Knochendichte, Meta-Analyse
APA, Harvard, Vancouver, ISO, and other styles
4

Stepaniuk, Kevin. "Bisphosphonate Related Osteonecrosis of the Jaws: A Review." Journal of Veterinary Dentistry 28, no. 4 (December 2011): 277–81. http://dx.doi.org/10.1177/089875641102800413.

Full text
Abstract:
Bisphosphonate use has increased in veterinary medicine over the last decade. During this time, bisphosphonate related osteonecrosis of the jaws (BRONJ) in human patients has been identified. Only recently was a dog model for BRONJ developed for human oral surgery and medicine. Veterinary patients treated with bisphosphonates may be at an increased risk for BRONJ. There has been little, to no, investigation of potential long term side-effects of bisphosphonate use in veterinary patients; potential sequelae are unknown. The history of bisphosphonates, their use, and BRONJ in veterinary patients are discussed.
APA, Harvard, Vancouver, ISO, and other styles
5

Thirunavukarasu, Ananthi, Hugo Grancho Pinto, and Kevin Guy Seymour. "Bisphosphonate and Implant Dentistry – is it Safe?" Primary Dental Journal 4, no. 3 (September 2015): 30–33. http://dx.doi.org/10.1308/205016815815944650.

Full text
Abstract:
Bisphosphonates are a group of drugs that are commonly used to alter bone metabolism in order to prevent bone loss in diseases such as osteoporosis and bone cancers. Unfortunately, the use of bisphosphonates has been associated with bisphosphonate-related osteonecrosis of the jaws. The debate as to whether it is wise to consider implant therapy in patients being treated with bisphosphonate therapy remains a grey area. This review will present the latest evidence and guidelines available on bisphosphonates and their possible effects on implant dentistry. The risk factors, co-morbidities, clinical presentation and findings from various imaging modalities for bisphosphonate-related osteonecrosis of the jaws are highlighted. The management of patients being treated with bisphosphonates, in whom dental implants might be considered or have already been placed, will also be discussed. Finally, the areas requiring future research are considered.
APA, Harvard, Vancouver, ISO, and other styles
6

Kawai, Toshiyuki, Kohei Nishitani, Yaichiro Okuzu, Koji Goto, Yutaka Kuroda, Shinichi Kuriyama, Shinichiro Nakamura, and Shuichi Matsuda. "Bisphosphonate use is associated with a decreased joint narrowing rate in the non-arthritic hip." Bone & Joint Research 11, no. 11 (November 1, 2022): 826–34. http://dx.doi.org/10.1302/2046-3758.1111.bjr-2022-0155.r1.

Full text
Abstract:
Aims The preventive effects of bisphosphonates on articular cartilage in non-arthritic joints are unclear. This study aimed to investigate the effects of oral bisphosphonates on the rate of joint space narrowing in the non-arthritic hip. Methods We retrospectively reviewed standing whole-leg radiographs from patients who underwent knee arthroplasties from 2012 to 2020 at our institute. Patients with previous hip surgery, Kellgren–Lawrence grade ≥ II hip osteoarthritis, hip dysplasia, or rheumatoid arthritis were excluded. The rate of hip joint space narrowing was measured in 398 patients (796 hips), and the effects of the use of bisphosphonates were examined using the multivariate regression model and the propensity score matching (1:2) model. Results A total of 45 of 398 (11.3%) eligible patients were taking an oral bisphosphonate at the time of knee surgery, with a mean age of 75.8 years (SD 6.2) in bisphosphonate users and 75.7 years (SD 6.8) in non-users. The mean joint space narrowing rate was 0.04 mm/year (SD 0.11) in bisphosphonate users and 0.12 mm/year (SD 0.25) in non-users (p < 0.001). In the multivariate model, age (standardized coefficient = 0.0867, p = 0.016) and the use of a bisphosphonate (standardized coefficient = −0.182, p < 0.001) were associated with the joint space narrowing rate. After successfully matching 43 bisphosphonate users and 86 non-users, the joint narrowing rate was smaller in bisphosphonate users (p < 0.001). Conclusion The use of bisphosphonates is associated with decreased joint degeneration in non-arthritic hips after knee arthroplasty. Bisphosphonates slow joint degeneration, thus maintaining the thickness of joint cartilage in the normal joint or during the early phase of osteoarthritis. Cite this article: Bone Joint Res 2022;11(11):826–834.
APA, Harvard, Vancouver, ISO, and other styles
7

Bourrion, Bastien, Cécile Souty, Lucie Fournier, Ana-Maria Vilcu, Thierry Blanchon, Pierre-Yves Böelle, Thomas Hanslik, and Mathilde François. "Bisphosphonate Use and Hospitalization for Hip Fractures in Women: An Observational Population-Based Study in France." International Journal of Environmental Research and Public Health 18, no. 16 (August 20, 2021): 8780. http://dx.doi.org/10.3390/ijerph18168780.

Full text
Abstract:
Bisphosphonates are widely used in the treatment of women at risk of osteoporotic hip fracture; however, the overall effectiveness of bisphosphonates in the prevention of osteoporotic fractures has not been studied in real life. To investigate whether the use of bisphosphonates in women aged 50 years and over is associated with a decrease in hospitalization for osteoporotic hip fractures, a historical prospective cohort study was conducted between 2009 and 2016 from a permanent representative sample consisting of 1/97 of the French health insurance beneficiaries. Bisphosphonate use was defined according to medication persistence and adherence regarding bisphosphonate dispensations. The primary outcome was the hospitalization rate for osteoporotic hip fracture. Among the 81,268 women included, 2005 were exposed to bisphosphonates. The median time of bisphosphonate exposure was 12 (IQR, 3–29) and 17 (IQR, 5–42) months for the persistence and adherence definitions, respectively. Exposure to bisphosphonates was not associated with a decrease in hospitalization for hip fracture: weighted HRadherence = 0.66 (95% CI, 0.33 to 1.33); HRpersistance = 0.77 (95% CI, 0.38 to 1.57). In real life, bisphosphonate use does not appear to reduce hospitalization for hip fractures, as to date, it is probably prescribed as primary prevention and for a duration too short to be effective.
APA, Harvard, Vancouver, ISO, and other styles
8

Lloyd, Ashley A., Bernd Gludovatz, Christoph Riedel, Emma A. Luengo, Rehan Saiyed, Eric Marty, Dean G. Lorich, et al. "Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance." Proceedings of the National Academy of Sciences 114, no. 33 (July 31, 2017): 8722–27. http://dx.doi.org/10.1073/pnas.1704460114.

Full text
Abstract:
Bisphosphonates are the most widely prescribed pharmacologic treatment for osteoporosis and reduce fracture risk in postmenopausal women by up to 50%. However, in the past decade these drugs have been associated with atypical femoral fractures (AFFs), rare fractures with a transverse, brittle morphology. The unusual fracture morphology suggests that bisphosphonate treatment may impair toughening mechanisms in cortical bone. The objective of this study was to compare the compositional and mechanical properties of bone biopsies from bisphosphonate-treated patients with AFFs to those from patients with typical osteoporotic fractures with and without bisphosphonate treatment. Biopsies of proximal femoral cortical bone adjacent to the fracture site were obtained from postmenopausal women during fracture repair surgery (fracture groups, n = 33) or total hip arthroplasty (nonfracture groups, n = 17). Patients were allocated to five groups based on fracture morphology and history of bisphosphonate treatment [+BIS Atypical: n = 12, BIS duration: 8.2 (3.0) y; +BIS Typical: n = 10, 7.7 (5.0) y; +BIS Nonfx: n = 5, 6.4 (3.5) y; −BIS Typical: n = 11; −BIS Nonfx: n = 12]. Vibrational spectroscopy and nanoindentation showed that tissue from bisphosphonate-treated women with atypical fractures was harder and more mineralized than that from bisphosphonate-treated women with typical osteoporotic fractures. In addition, fracture mechanics measurements showed that tissue from patients treated with bisphosphonates had deficits in fracture toughness, with lower crack-initiation toughness and less crack deflection at osteonal boundaries than that of bisphosphonate-naïve patients. Together, these results suggest a deficit in intrinsic and extrinsic toughening mechanisms, which contribute to AFFs in patients treated with long-term bisphosphonates.
APA, Harvard, Vancouver, ISO, and other styles
9

Ntep, Ntep David Bienvenue, Ernest Kenna, Siafa Antoine Bola, and Messanga Charles Bengondo. "The Potential Role of Angiogenic Osteoclast Inhibition in the Occurrence of Bisphosphonate-related Osteonecrosis of the Jaw." Case Reports in Dental Science 1, no. 1 (June 30, 2020): 15–21. http://dx.doi.org/10.46619/crds.2020.1-1004.

Full text
Abstract:
Bisphosphonate-related osteonecrosis of the jaw is a serious complication of systemic bisphosphonate administration, the mechanism of which remains unclear. Many hypotheses regarding pathophysiology are discussed, including the most commonly cited: suppression of bone remodeling and suppression of angiogenesis, but none of these would explain all the unique features of bisphosphonaterelated jaw osteonecrosis. Bisphosphonates are potent inhibitors of osteoclasts, and recent studies have shown that osteoclasts are important for bone angiogenesis. Therefore, we hypothesize that bisphosphonates inhibit osteoclastic stimulation of angiogenesis, thereby contributing to the occurrence of osteonecrosis of the jaws. This theory would partially explain the pathophysiology of bisphosphonate-related osteonecrosis of the jaw to the unfathomable.
APA, Harvard, Vancouver, ISO, and other styles
10

Sawatari, Yoh, and Robert E. Marx. "Bisphosphonates and Bisphosphonate Induced Osteonecrosis." Oral and Maxillofacial Surgery Clinics of North America 19, no. 4 (November 2007): 487–98. http://dx.doi.org/10.1016/j.coms.2007.07.003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Bisphosphonate"

1

Roelofs, Anke. "Anti-tumour mechanisms of action bisphosphonates and bisphosphonate analogues." Thesis, University of Oxford, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.436994.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Debbabi, M., M. Othmani, and A. Aissa. "Nanocrystalline Hydroxyapatite-Bisphosphonate Composites." Thesis, Sumy State University, 2013. http://essuir.sumdu.edu.ua/handle/123456789/35199.

Full text
Abstract:
The direct synthesis of hydroxyapatite─1,8-octan-bisphosphonic acid (HAp─BISPH) nanocrystals has been carried out in presence of increasing amounts of BISPH in solution, by hydrothermal method at 120 °C for 15 h. XRD, IR, NMR-MAS (31P, 1H and 13C), TEM, AFM, TGA and chemical analysis were used to characterize the structure, morphology and composition of the products. X-ray powder diffraction patterns show that the incorporation of bisphosphonate moieties induces a significant loss of the material crystallin-ity and a clear decrease of the crystallite size. TEM and AFM images show that the precipitated apatite particles prepared in the presence of this bisphosphonic acid are nanosized. The IR and NMR-MAS 1H spectroscopy show that the BISPH can replace the OH− groups of the apatitic structure. When you are citing the document, use the following link http://essuir.sumdu.edu.ua/handle/123456789/35199
APA, Harvard, Vancouver, ISO, and other styles
3

Sharma, Chakrabhavi Gundurao Dileep. "Role of Inflammation and Angiogenesis in Aetiology of Bisphosphonate-related Osteonecrosis of the Jaws." Thesis, Griffith University, 2016. http://hdl.handle.net/10072/367505.

Full text
Abstract:
Bisphosphonates (BPs) are a group of anti-resorptive agents that possess high binding affinity to bone mineral. They accumulate in bone and are released during bone turnover to inhibit resorption after their internalisation by osteoclasts. This has been described as the principal mechanism of action of BPs, warranting their use in various bone depleting conditions such as osteoporosis, Paget’s disease, metastatic bone diseases (breast cancer, prostate cancer and multiple myeloma primary sites) and paediatric osteogenesis imperfecta. However, BPs are associated with a significant adverse effect that selectively occurs in jaw bones, termed Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ). While the pathogenesis of BRONJ is not yet clearly understood, recent focus of research has been on their anti-angiogenic properties that could significantly contribute to the aetiopathogenic process by which the avascular necrosis of the jaw bone ensues. The focus of this project was to explore the mechanism by which the anti-angiogenic properties of BPs can lead to the occurrence of BRONJ lesions and subsequently formulate a localised approach for prevention of this painful and debilitating condition.
Thesis (PhD Doctorate)
Doctor of Philosophy (PhD)
School of Dentistry and Oral health
Griffith Health
Full Text
APA, Harvard, Vancouver, ISO, and other styles
4

Duan, Ke. "Bisphosphonate-containing coatings for bone implants." Thesis, University of British Columbia, 2007. http://hdl.handle.net/2429/31288.

Full text
Abstract:
Bone implants are extensively used to replace joints affected by skeletal problems. Challenges remain to further improve the clinical outcomes of implants. A fast and strong implant fixation would improve the patient's quality of life and reduce implant failure risk. The service life of implants needs to be extended, particularly for the younger patients. A logical approach to these challenges is to control the peri-implant bone formation and remodeling. Bisphosphonate drugs, potent osteoclast inhibitors, are the appropriate choice for this purpose. This thesis studied bisphosphonate-containing coatings on bone implants for local drug delivery. A reproducible electrolytic deposition (ELD) process was developed to prepare calcium phosphate (CaP) coatings on Ti and Ta as bisphosphonate carrier. The ELD parameters were experimentally determined. Microporous coatings containing octacalcium-phosphate were obtained; the pore sizes were 0.5-1 μm. The ELD current showed a rapid Cottrell-type decay followed by a prolonged nearly-constant stage, corresponding to proton reduction and molecular water electrolysis, respectively. Alendronate was chemically adsorbed on the CaP coating, and the in vitro release from the coated porous Ta implant was slow, with ~10% released after 7 days. The ELD technique was extended to process solid bisphosphonate coatings. Uniform coatings of calcium-etidronate and calcium-alendronate were deposited on Ti and porous Ta. The ELD process did not alter the molecular structures of the bisphosphonates. The solubility of the coatings in a "physiological" buffer solution was 6 x 10⁻⁵ M for Ca-etidronate and 2.5 x 10⁻⁴ M for calcium alendronate. In vitro release of alendronate from the calcium-alendronate-coated porous Ta was completed within 3 days, and the alendronate concentration was below the solubility limit. To evaluate the in vivo performance, porous Ta implants coated with the bisphosphonate-containing coatings were implanted into rabbit tibial diaphyses together with control implants. Four weeks after implantation, the CaP-coated implants with chemically adsorbed alendronate showed significantly higher total new bone area and pushout strength. The implants with calcium alendronate solid coating showed similar implant fixation and new bone area to the native Ta implants. Eight weeks after implantation, the differences in push-out strength and total new bone area were not significant among different implants.
Applied Science, Faculty of
Materials Engineering, Department of
Graduate
APA, Harvard, Vancouver, ISO, and other styles
5

Stewart, Charlotte. "Structure activity relationships of bisphosphonate analogues." Thesis, University of Aberdeen, 2010. http://digitool.abdn.ac.uk:80/webclient/DeliveryManager?pid=128207.

Full text
Abstract:
The nitrogen-containing bisphosphonates (NBPs) are the most widely used treatment for diseases involving excessive osteoclastic bone resorption, such as osteoporosis. The clinical efficacy of NBPs is due in large part to their affinity for bone mineral, but it has been suggested that lowering affinity may have benefits due to altered distribution and duration of action possibly allowing direct anti-tumour effects. In addition, the phosphonocarboxylate (PC) analogues inhibit prenylation more selectively through a different enzyme target, Rab geranylgeranyl transferase (RGGT), which may offer additional benefits by reducing side-effects associated with farnesyl diphosphate synthase (FPPS) inhibition. Using fluorescent analogues of PCs and NBPs demonstrated that mineral affinity not only affects initial bone-binding, but also influences desorption, reattachment and penetration at the bone surface, suggesting that lower affinity compounds have lower retention and increased access to other cell types, such as tumour cells. The work presented aimed to investigate the potential of low affinity analogues by characterising their intracellular potency for inhibiting their target enzymes. The results showed that modification to the phosphonate groups to produce phosphonoalkylphosphinate analogues reduced potency for inhibiting FPPS. By contrast, removal of one of the phosphonate groups to give a monophosphonate changed the target enzyme to RGGT. Modifications to the R1 side-chain (substituting with hydrogen or a halogen) of both NBPs and PCs were studied and showed contrasting results, modifications to the R1 side-chain of NBPs affect their ability to inhibit FPPS whereas the same modification to PCs is insignificant for inhibiting RGGT. This showed the distinction between the structural requirements for inhibition of RGGT and FPPS and furthers the understanding of the structure-activity relationships of both NBPs and PCs which could guide future drug design. Within this thesis the most potent inhibitor of RGGT to date, 3-IPEHPC, was characterised which in addition to having therapeutic potential may be used as tool to investigate the importance of Rab prenylation for cellular function.
APA, Harvard, Vancouver, ISO, and other styles
6

Benford, Helena L. "Molecular pathways of bisphosphonate-induced apoptosis." Thesis, University of Aberdeen, 2000. http://digitool.abdn.ac.uk/R?func=search-advanced-go&find_code1=WSN&request1=AAIU602025.

Full text
Abstract:
Recent studies have proposed that non-nitrogen-containing and nitrogen- containing bisphosphonate drugs inhibit osteoclastic bone resorption by different molecular mechanisms. The aim of this thesis was to investigate the molecular mechanisms of action of bisphosphonates in macrophages and osteoclasts and, in particular, the activation of caspase proteases and their role in apoptotic cell death. Apoptosis of J774 macrophages induced by nitrogen-containing bisphosphonates was found to involve the activation of caspase-3. By contrast, non-nitrogen- containing bisphosphonates did not cause caspase activation or J774 apoptosis, indicating that these bisphosphonates have different cellular effects. Further studies demonstrated that nitrogen-containing bisphosphonates induced J774 macrophage apoptosis by inhibiting the mevalonate pathway and preventing protein farnesylation and/or geranylgeranylation, since these compounds inhibited incorporation of [14 C] mevalonate into isoprenylated proteins, and addition of cell-permeable intermediates of the mevalonate pathway (FPP and GGPP) prevented bisphosphonate-induced apoptosis. Apoptosis of J774 macrophages induced by nitrogen-containing bisphosphonates or mevastatin (another inhibitor of the mevalonate pathway) was dependent on protein synthesis, since cycloheximide effectively prevented the activation of caspase-3 and prevented J774 cell apoptosis. Both nitrogen-containing bisphosphonates and non-nitrogen-containing bisphosphonates caused caspase-3 activation and apoptosis of rabbit and human osteoclasts in vitro. The active form of caspase-3 was detected in apoptotic osteoclasts by immunofluorescence staining, whilst caspase-3 activity was visualised in osteoclasts using a cell-permeable, fluorogenic substrate and detected in cell lysates using caspase-specific substrates. Bisphosphonate-induced osteoclast apoptosis involved loss of mitochondrial membrane potential and could be prevented by a specific inhibitor of caspase-3/-7. The ability of bisphosphonates to activate caspase-3 and cause apoptosis was mimicked by GGTI-298, a specific inhibitor of protein geranylgeranylation, suggesting that caspase activation and apoptosis in osteoclasts induced by bisphosphonates is the consequence of loss of geranylgeranylated proteins. Bisphosphonate-induced osteoclast apoptosis and inhibition of bone resorption in vitro was suppressed by RANK ligand. This did notappear to involve changes in Akt phosphorylation or increased expression of cIAP-1 or cIAP-2. These studies have helped to identify the molecular mechanisms of action of bisphosphonate drugs and have provided new insights into the involvement of caspases in osteoclast apoptosis.
APA, Harvard, Vancouver, ISO, and other styles
7

White, Courtney Ellen. "Characteristics of bisphosphonate elution from orthopaedic implants." Thesis, McGill University, 2006. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=99121.

Full text
Abstract:
Bisphosphonates, drugs typically used to prevent bone loss for patients with osteoporosis, could also be used to enhance bone growth into porous implants. Since systemic administration of bisphosphonates is not appropriate for all patients, there is a need to develop a localized drug delivery system and characterize the drug release. The chemical affinity of bisphosphonates for hydroxyapatite was used to temporarily bind them to hydroxyapatite coatings on porous implants. Implants were immersed in aqueous solution and the drug elution was measured using UV spectrophotometry. With hydroxyapatite coating there was an initial burst of elution followed by more gradual drug release over several weeks. Without hydroxyapatite coating, all of the drug eluted in a maximum of three hours. This study served to demonstrate the feasibility of binding bisphosphonate compounds to hydroxyapatite coatings and characterized the elution characteristics as a function of time.
APA, Harvard, Vancouver, ISO, and other styles
8

Duan, Xuchen. "Physiological and biological mechanisms of bisphosphonate action." Thesis, University of Oxford, 2011. http://ora.ox.ac.uk/objects/uuid:36b0439d-2f89-4c1e-8bb3-941b4e6ee847.

Full text
Abstract:
Bisphosphonates (BPs) are stable analogues of pyrophosphate widely used for the treatment of bone diseases characterised by increased bone resorption. Studies over the years have shown that the pharmacological potencies of BPs are dependent both on their binding affinities for bone mineral and on their inhibitory actions on osteoclasts. In addition, potential effects on other cell types present locally in the environment of skeletal tissues have been reported. The present study systematically evaluated the relative mineral-binding affinities of individual BPs of clinically relevance in mixtures of these compounds and the changes with elution pH by using column chromatography with ceramic hydroxyapatite and fluoroapatite combined with mass spectrometric identification and quantitation of the individual BPs. The results indicate that pH has a profound effect on the ionisation of the phosphonate and R2 functional groups, with BPs having greater affinities at lower pH as shown by increased retention times. Moreover, two other approaches, namely using Langmuir adsorption isotherms and competition assays based on fluorescent BP, have been developed to assess the mineral-binding capacities and dissociation constants of BPs. These results suggest that there are substantial differences among BPs in their binding to hydroxyapatite. From the cellular aspect of my study, I present evidence for the anti-apoptotic effects of BPs in osteocytes and osteoblasts. However, the study of prosurvival signalling pathways involved in these cells needs to be optimised. The work described in this thesis provides novel insights into the physiological and biological mechanisms of BP action. My project has provided a better knowledge of the physicochemical properties of BPs, which are highly relevant to their differential distributions within bone, their biological potencies, and their durations of action. Additionally, the cell culture studies may provide new information on the cellular effects of BPs on osteocytes and osteoblasts.
APA, Harvard, Vancouver, ISO, and other styles
9

Roberts, Jacintha. "Studies on bisphosphonate elution from orthopaedic implants." Thesis, McGill University, 2008. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=112582.

Full text
Abstract:
In a 6-week rat model it was demonstrated that a small dose of peri-implant zoledronic acid (ZA) increased local bone formation 3-fold compared with controls. Ancillary in vitro studies using 14C-labeled ZA implant doses demonstrated biphasic elution profiles for implants coated with hydroxyapatite; complete ZA release occurred within one to three weeks in serum compared with only 60% ZA release after 12 weeks in water. Implants without hydroxyapatite coating showed more burst-type release profiles and full ZA elution within 24 hours of hydration in serum or water. Canine studies at 6 weeks using implants with 14C-labeled ZA showed that the compound remained localized, with the greatest ZA concentration immediately adjacent to the implant. Although there was evidence of skeletal ZA distribution via diffusion into the circulation, the levels were two orders of magnitude less than at the implant site.
APA, Harvard, Vancouver, ISO, and other styles
10

Phoebe, Erin, Jeff Pasteur, Marion Slack, and Jeannie Lee. "Fracture Risk with Bisphosphonate Use versus Concurrent Proton Pump Inhibitor and Bisphosphonate Use: A Systematic Review and Meta- Analysis." The University of Arizona, 2013. http://hdl.handle.net/10150/614271.

Full text
Abstract:
Class of 2013 Abstract
Specific Aims: To determine whether concurrent use of a proton pump inhibitor (PPI) and a bisphosphonate represent an additional fracture risk compared with bisphosphonate use alone and to identify an increased risk of any particular fracture type. Methods: This study was a systematic review and meta-analysis of data collected from PubMed, Cochrane, OVID Medline, Google Scholar, and IPA. The authors utilized the search terms: bisphosphonate, fractures and proton pump inhibitors. Studies which met criteria of being English-language with adults 18 years of age and older were included. Main Results: The studies were cohort studies and primarily evaluated older adults. The summary effect was that use of a PPI with a bisphosphonate showed a slight increase in fracture risk when compared to bisphosphonate-only therapy (odds ratio [OR] 1.12, 95% confidence interval [CI], 1.06-1.18). Systematic review of similar studies showed varied results, making difficult any conclusion regarding fracture risk among the treatments. Conclusion: In this analysis, PPI + bisphosphonate demonstrated a slight increase in fracture rate without inference to an increase in any particular fracture type compared with bisphosphonate only. However, there is minimal data on the association or causal effect of this increase. The few studies available offered contradictory results. Additionally, database studies are subject to the possibility of residual confounding. Further research using randomized control trial (RCT) design evaluating long term use of bisphosphonates with or without PPI and their impact on fractures is needed to determine if there is an additional degree of fracture risk from the concurrent use.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Bisphosphonate"

1

Maria, Bijvoet Olav Leonardus, ed. Bisphosphonate on bones. Amsterdam: Elsevier, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Girard, Bruno. Exploring high dose effects of a bisphosphonate (HEBP) on osteogenesis in vitro. [Toronto: Faculty of Dentistry, University of Toronto], 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Catherine, Allison, and Canadian Coordinating Office for Health Technology Assessment., eds. An assessment of bisphosphonate drugs to manage pain secondary to bone metastases. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Marx, Robert E. Oral & intravenous bisphosphonate-induced osteonecrosis of the jaws: History, etiology, prevention, and treatment. Chicago: Quintessence Pub. Co., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Rebecca, Wong, and Canadian Coordinating Office for Health Technology Assessment., eds. Bisphosphonate agents for the management of pain secondary to bone metastases: A systematic review of effectiveness and safety. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws: History, etiology, prevention, and treatment. 2nd ed. Chicago: Quintessence Pub. Co., Inc., 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ponte, Francesco Saverio De. Bisphosphonates and osteonecrosis of the jaw: A multidisciplinary approach. Milan: Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chan, Cary Chung-Keung. Effects of cyclical parathyroid hormone (1-34) fragments and (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate treatment on bone in ovariectomized rats. Ottawa: National Library of Canada, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bartl, Reiner, Emmo von Tresckow, and Christoph Bartl. Bisphosphonat-Manual. Berlin, Heidelberg: Springer Berlin Heidelberg, 2006. http://dx.doi.org/10.1007/3-540-31271-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Brunner, Kurt W., Herbert Fleisch, and Hans-Jörg Senn, eds. Bisphosphonates and Tumor Osteolysis. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-83668-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Bisphosphonate"

1

Ruth, Todd H., and Veena Graff. "Bisphosphonate Infusion Therapy." In Infusion Therapy, 107–13. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-17478-1_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bartl, Reiner. "Bisphosphonate und Denosumab." In Osteoporose in der Praxis, 117–30. Berlin, Heidelberg: Springer Berlin Heidelberg, 2022. http://dx.doi.org/10.1007/978-3-662-64207-8_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bartl, Reiner. "Bisphosphonate und Denosumab." In essentials, 31–44. Berlin, Heidelberg: Springer Berlin Heidelberg, 2022. http://dx.doi.org/10.1007/978-3-662-65475-0_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bartl, Reiner, and Christoph Bartl. "Bisphosphonate und Denosumab." In Das Osteoporose Manual, 205–23. Berlin, Heidelberg: Springer Berlin Heidelberg, 2021. http://dx.doi.org/10.1007/978-3-662-62528-6_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Reszka, Alfred A. "Bisphosphonate Mechanisms of Action." In Osteoporosis, 443–68. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-459-9_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Watts, Nelson B. "Bisphosphonate Therapy for Osteoporosis." In Atlas of Osteoporosis, 189–94. London: Current Medicine Group, 2003. http://dx.doi.org/10.1007/978-1-4757-4561-0_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bone, Henry. "Bisphosphonate Therapy for Postmenopausal Osteoporosis." In Osteoporosis in Clinical Practice, 133–42. London: Springer London, 2004. http://dx.doi.org/10.1007/978-0-85729-402-9_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mawardi, Hani H., Nathaniel S. Treister, and Sook-Bin Woo. "Bisphosphonate-Associated Osteonecrosis of the Jaws." In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 929–40. Ames, USA: John Wiley & Sons, Inc., 2013. http://dx.doi.org/10.1002/9781118453926.ch112.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zavras, Athanasios. "Bisphosphonate Related Osteonecrosis of the Jaw." In Genomics, Personalized Medicine and Oral Disease, 311–31. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-17942-1_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Cairoli, Elisa, and Iacopo Chiodini. "Biomarkers of Bisphosphonate Failure in Osteoporosis." In Biomarkers in Bone Disease, 1065–85. Dordrecht: Springer Netherlands, 2017. http://dx.doi.org/10.1007/978-94-007-7693-7_45.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Bisphosphonate"

1

Kozloff, Kenneth M., Leo I. Volakis, Joan C. Marini, and Michelle S. Caird. "Near-Infrared Imaging Reveals Site- and Age-Specific Localization of Bisphosphonate Delivery and Retention in Model of Osteogenesis Imperfecta." In ASME 2009 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2009. http://dx.doi.org/10.1115/sbc2009-205344.

Full text
Abstract:
Bisphosphonate use has expanded beyond traditional applications, such as the prevention of osteoporosis, into non-traditional pediatric low bone mass diseases including osteogenesis imperfecta (OI) [1]. Despite enthusiasm, some questions remain on the overall effectiveness and implications of long-term treatment. In the Brtl/+ mouse model for OI, bisphosphonate treatment improves bone size, but bending strength fails to increase to proportionate levels and bones remain brittle [2]. Complications associated with long-term bisphosphonate treatment have been noted in other systems [3,4] leading to a need for critical information describing local drug-cell interactions responsible for these observations. The purpose of this study was to validate a fluorescent bisphosphonate analog, far-red fluorescent pamidronate (FRFP) [5] as a biomarker of bisphosphonate deposition and retention in vivo to monitor local drug concentration in a site-specific manner.
APA, Harvard, Vancouver, ISO, and other styles
2

Gnant, M. "Abstract PL02: Adjuvant bisphosphonate therapy in breast cancer." In Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/0008-5472.sabcs13-pl02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zhou, Yilu, Lauren Resutek, Liyun Wang, and X. Lucas Lu. "Effects of Bisphosphonate on Long-Term Culture of Cartilage Allografts." In ASME 2013 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/sbc2013-14635.

Full text
Abstract:
Zoledronic acid (ZA), an FDA approved bisphosphonate (BP) medicine, is widely used for the treatment of osteoclast-related bone loss diseases [1]. Our previous study has found that systemic administration of ZA could dramatically suppress the development of post-traumatic osteoarthritis (PTOA) in the DMM (destabilization of the medial meniscus) mouse model, a model recapitulating the altered joint loading associated with PTOA [2]. This finding is consistent with a few similar studies using different animal models [3]. However, little is known about the cellular and biochemical mechanisms of BP mediated chondro-protection in PTOA pathogenesis. Studies have shown that PTOA often initiates from the apoptosis and altered metabolism of cartilage chondrocytes. In this study, we will investigate the direct effects of ZA on the metabolisms of chondrocytes using long-term in vitro culture of cartilage allografts. As one of the earliest responses of chondrocytes to mechanical stimulation, intracellular calcium ([Ca 2+] i) signaling is the upstream of numerous mechanotransduction pathways [4]. We hypothesize that the chondro-protective mechanisms of ZA could be represented by the characteristics of [Ca 2+] i signaling of in situ chondrocytes. Our specific aims were to: (i) compare the in situ spontaneous [Ca 2+] i responses of chondrocytes cultured in non-ZA and ZA supplemented environments, and (ii) compare the biomechanical properties of cartilage allografts under the two culture conditions.
APA, Harvard, Vancouver, ISO, and other styles
4

Rudnick-Glick, S., E. Corem-Salkmon, I. Grinberg, E. Gluz, and S. Margel. "Biodegradable bisphosphonate nanoparticles for imaging and therapeutic applications in osteosarcoma." In SPIE Nanoscience + Engineering, edited by Hooman Mohseni, Massoud H. Agahi, and Manijeh Razeghi. SPIE, 2015. http://dx.doi.org/10.1117/12.2186765.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Papineni, Rao V., Thirupandiyur Udayakumar, Mansoor Ahmed, John Pizzonia, and Alan Pollack. "Abstract 5327: In vivo fluorescence imaging of solid tumor-bisphosphonate interaction." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-5327.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Rydzik, Anna, Joanna Zuberek, Joanna Kowalska, Edward Darżynkiewicz, and Jacek Jemielity. "Bisphosphonate modification in tetraphosphate 5'mRNA cap analogs – synthesis and biochemical properties." In XIVth Symposium on Chemistry of Nucleic Acid Components. Prague: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 2008. http://dx.doi.org/10.1135/css200810444.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Newton, Kathe`rine, Ruth Keeble, and Nikki Reed. "P-204 Bisphosphonate treatment in bone metastases: an interventional outpatient clinic model." In People, Partnerships and Potential, 16 – 18 November 2016, Liverpool. British Medical Journal Publishing Group, 2016. http://dx.doi.org/10.1136/bmjspcare-2016-001245.225.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

sohrabi, Beheshteh, and Sara Mashkoori. "The theoretical study of bisphosphonate derivatives as drug for inhibition of cancer." In The 14th International Electronic Conference on Synthetic Organic Chemistry. Basel, Switzerland: MDPI, 2010. http://dx.doi.org/10.3390/ecsoc-14-00388.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Yutani, Y., and Y. Yamano. "SAT0056 Bisphosphonate modulates ectopic bone formation after hip arthroplasty -with japanese cases-." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.431.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Santos, Miguel, Sónia Teixeira, Maria Fernandes, João Rodrigues, and Luís Branco. "Antitumor and osteogenic activity of bisphosphonate-based organic salts and ionic liquids." In 6th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2020. http://dx.doi.org/10.3390/ecmc2020-07924.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Bisphosphonate"

1

Chen, Po-Wei, Hsiao-Yuan Su, Chih-Hsing Wu, Jih-I. Yeh, Ching-Hui Loh, Li-Yu Chen, Huei-Kai Huang, and Shu-Man Lin. Association of Bisphosphonates with Risk of Incident Diabetes and Glycemic Control: A Protocol of Systematic Review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0125.

Full text
Abstract:
Review question / Objective: To determine the association between bisphosphonate use and the risk of incident diabetes and glycemic control in adults with updated evidence from clinical trials and observational studies. Eligibility criteria: The inclusion criteria for studies assessing risk of incident diabetes are as follows: (1) availability of data on bisphosphonate use in individuals without diabetes; (2) evaluation of the risk of diabetes for bisphosphonate users compared with controls; and (3) either clinical trials or observational studies. To assess effects of bisphosphonates on glycemic control, we will include studies with: (1) availability of data on bisphosphonate use in individuals regardless of diabetes state; (2) evaluation of the glycemic parameters, including fasting blood glucose (FBG) or glycosylated hemoglobin (HbA1c), for bisphosphonate users compared with controls; (3) report sufficient data on the change in glycemic parameters (FBG and HbA1c) before and after bisphosphonate use or placebo/comparison use; (4) either clinical trials or observational studies. We will exclude studies with only a single arm without comparison.
APA, Harvard, Vancouver, ISO, and other styles
2

Palmer, Matthew R. Bisphosphonate-Based Contrast Agents for Radiological Imaging of Microcalcifications. Fort Belvoir, VA: Defense Technical Information Center, September 2004. http://dx.doi.org/10.21236/ada431695.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Palmer, Matthew R. Bisphosphonate-Based Contrast Agents for Radiological Imaging of Microcalcifications. Fort Belvoir, VA: Defense Technical Information Center, March 2006. http://dx.doi.org/10.21236/ada468525.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dioguardi, Mario. Post-Extraction Complications in Patients Undergoing Oral Bisphosphonate Therapy. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0035.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Selander, Katri. Toll-Like Receptor Pathway as Mediator of Bisphosphonate Effects in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, July 2005. http://dx.doi.org/10.21236/ada439205.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Price, Chrisopher. Bisphosphonates in the Prevention of Post-Traumatic Osteoarthritis. Fort Belvoir, VA: Defense Technical Information Center, July 2014. http://dx.doi.org/10.21236/ada615280.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Xiang, Kemeng, Huiming Hou, and Ming Zhou. The efficacy of Cerus and Cucumis Polypeptide injection combined with Bisphosphonates on postmenopausal women with osteoporosis:A protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0067.

Full text
Abstract:
Review question / Objective: The aim of this review is to evaluate the effectiveness of Cerus and Cucumis Polypeptide injection combined with Bisphosphonates for postmenopausal osteoporosis. Condition being studied: Postmenopausal osteoporosis (PMOP) is a disorder of bone metabolism caused by estrogen deficiency in women after menopause, which manifests clinically as pain, spinal deformities and even fragility fractures, affecting the quality of life of patients and possibly shortening their life span. Bisphosphonates are commonly used to control and delay the progression of the disease, improve the patient's symptoms and reduce the incidence of fragility fractures. However, single drugs are still lacking in controlling the progression of the disease, and the combination of drugs is the clinical priority.
APA, Harvard, Vancouver, ISO, and other styles
8

Huang, Huei-Kai, Shu-Man Lin, Carol Chiung-Hui Peng, Kashif M. Munir, Khulood Bukhari, Kory Jaggon, and Yunting Fu. Bisphosphonates and the risk of stroke: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0085.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

KHANOV, A. G., L. I. Datchina, and S. S. Brovkina. DO WE NEED A BREAKTHROUGH IN OSTEOPOROSIS AND HOW TO ORGANIZE IT (THE PHARMACOLOGICAL JUSTIFICATION IN PREMEDICATION FOR INTRAVENOUS BISPHOSPHONATES). "PLANET", 2019. http://dx.doi.org/10.18411/978-5-907192-54-6-2019-xxxvi-174-186.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wu, Yao, Fangyong Wang, and Zhenrong Zhang. Efficacy and Safety of Bisphosphonates Analogues in Persons with Osteoporosis after Spinal Cord Injury: a Systematic Review and Meta-Analysis of Randomized Controlled Trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2020. http://dx.doi.org/10.37766/inplasy2020.7.0013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Bisphosphonate' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography